Document Detail


Nicotine decreases food intake through activation of POMC neurons.
MedLine Citation:
PMID:  21659607     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Smoking decreases appetite, and smokers often report that they smoke to control their weight. Understanding the neurobiological mechanisms underlying the anorexic effects of smoking would facilitate the development of novel treatments to help with smoking cessation and to prevent or treat obesity. By using a combination of pharmacological, molecular genetic, electrophysiological, and feeding studies, we found that activation of hypothalamic α3β4 nicotinic acetylcholine receptors leads to activation of pro-opiomelanocortin (POMC) neurons. POMC neurons and subsequent activation of melanocortin 4 receptors were critical for nicotinic-induced decreases in food intake in mice. This study demonstrates that nicotine decreases food intake and body weight by influencing the hypothalamic melanocortin system and identifies critical molecular and synaptic mechanisms involved in nicotine-induced decreases in appetite.
Authors:
Yann S Mineur; Alfonso Abizaid; Yan Rao; Ramiro Salas; Ralph J DiLeone; Daniela Gündisch; Sabrina Diano; Mariella De Biasi; Tamas L Horvath; Xiao-Bing Gao; Marina R Picciotto
Related Documents :
12709477 - Genetically modified soybeans and food allergies.
11964687 - The role of plant panallergens in sensitization to natural rubber latex.
16784017 - Exotic pets are new allergenic sources: allergy to iguana.
8939157 - Identification of a 60 kd cross-reactive allergen in pollen and plant-derived food.
20627107 - Balancing organization and flexibility in foraging dynamics.
10181517 - Orthopedic devices: classification and reclassification of pedicle screw spinal systems...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Science (New York, N.Y.)     Volume:  332     ISSN:  1095-9203     ISO Abbreviation:  Science     Publication Date:  2011 Jun 
Date Detail:
Created Date:  2011-06-10     Completed Date:  2011-06-21     Revised Date:  2014-04-16    
Medline Journal Info:
Nlm Unique ID:  0404511     Medline TA:  Science     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1330-2     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Alkaloids / metabolism
Animals
Azocines / metabolism
Eating / drug effects*
Ganglionic Stimulants / pharmacology*
Male
Melanocortins / metabolism
Mice
Mice, Inbred C57BL
Mice, Knockout
Neurons / drug effects,  metabolism
Nicotine / pharmacology*
Nicotinic Agonists / pharmacology
Pro-Opiomelanocortin / metabolism*
Quinolizines / metabolism
Receptors, Nicotinic / metabolism
Grant Support
ID/Acronym/Agency:
AA15632/AA/NIAAA NIH HHS; DA00436/DA/NIDA NIH HHS; DA017173/DA/NIDA NIH HHS; DA14241/DA/NIDA NIH HHS; DK070039/DK/NIDDK NIH HHS; DK070723/DK/NIDDK NIH HHS; DK080000/DK/NIDDK NIH HHS; DP1 OD006850-02/OD/NIH HHS; K02 DA000436-10/DA/NIDA NIH HHS; OD006850/OD/NIH HHS; P20 RR016467-10/RR/NCRR NIH HHS; P50 AA015632-10/AA/NIAAA NIH HHS; R01 DA014241/DA/NIDA NIH HHS; R01 DA014241-10/DA/NIDA NIH HHS; R01 DA017173-07/DA/NIDA NIH HHS; R01 DK070039/DK/NIDDK NIH HHS; R01 DK070039-04/DK/NIDDK NIH HHS; R01 DK070723-05/DK/NIDDK NIH HHS; R01 DK070723-05S2/DK/NIDDK NIH HHS; R01 DK080000-04/DK/NIDDK NIH HHS; RR016467/RR/NCRR NIH HHS; U19 CA148127/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Alkaloids; 0/Azocines; 0/Ganglionic Stimulants; 0/Melanocortins; 0/Nicotinic Agonists; 0/Quinolizines; 0/Receptors, Nicotinic; 0/nicotinic receptor alpha3beta4; 485-35-8/cytisine; 54-11-5/Nicotine; 66796-54-1/Pro-Opiomelanocortin
Comments/Corrections
Comment In:
Cell Metab. 2011 Aug 3;14(2):145-7   [PMID:  21803282 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Adaptation and evolutionary rescue in metapopulations experiencing environmental deterioration.
Next Document:  Part 3: Pharmacogenetic variability in phase II anticancer drug metabolism.